ICAM-1-related long non-coding RNA: promoter analysis and expression in human retinal endothelial cells

Objective Regulation of intercellular adhesion molecule (ICAM)-1 in retinal endothelial cells is a promising druggable target for retinal vascular diseases. The ICAM-1-related (ICR) long non-coding RNA stabilizes ICAM-1 transcript, increasing protein expression. However, studies of ICR involvement in disease have been limited as the promoter is uncharacterized. To address this issue, we undertook a comprehensive in silico analysis of the human ICR gene promoter region. Results We used genomic evolutionary rate profiling to identify a 115 base pair (bp) sequence within 500 bp upstream of the transcription start site of the annotated human ICR gene that was conserved across 25 eutherian genomes. A second constrained sequence upstream of the orthologous mouse gene (68 bp; conserved across 27 Eutherian genomes including human) was also discovered. Searching these elements identified 33 matrices predictive of binding sites for transcription factors known to be responsive to a broad range of pathological stimuli, including hypoxia, and metabolic and inflammatory proteins. Five phenotype-associated single nucleotide polymorphisms (SNPs) in the immediate vicinity of these elements included four SNPs (i.e. rs2569693, rs281439, rs281440 and rs11575074) predicted to impact binding motifs of transcription factors, and thus the expression of ICR and ICAM-1 genes, with potential to influence disease susceptibility. We verified that human retinal endothelial cells expressed ICR, and observed induction of expression by tumor necrosis factor-α. Electronic supplementary material The online version of this article (10.1186/s13104-018-3384-8) contains supplementary material, which is available to authorized users.


Background
Retinal vascular diseases occur commonly and represent a major cause of blindness in developing and developed nations. These conditions include diabetic retinopathy, major retinal vessel occlusions, sickle cell retinopathy, retinopathy of prematurity and uveitis [1]. A key feature of the pathology of any retinal vasculopathy is overexpression of endothelial adhesion molecules in response to stimuli such as inflammatory molecules, toxic metabolites and hypoxia. The increased expression of adhesion molecules promotes leukocyte interactions with the endothelium, resulting in leukostasis, migration of leukocytes into the tissue and/or endothelial cell apoptosis [1]. Present evidence [2][3][4][5][6] implicates intercellular adhesion molecule (ICAM)-1, which is expressed at relatively high levels on human retinal endothelium [7], as a critical player.
Targeting retinal endothelial ICAM-1 for therapeutic purposes has been entertained [1]. However, ICAM-1 plays an important role in host immune defense and complete blockade would pose the risk of infection. In previously published work [8], we showed that a stimulus-induced increase in ICAM-1, but not its basal level, might be reduced by manipulating gene expression. Small interfering RNA knock-down of the multi-functional transcription factor (TF), nuclear factor κ-light-chainenhancer of activated B cells (NF-κB)1, in human retinal endothelial cells significantly reduced a tumor necrosis factor (TNF)-α-induced increase in ICAM-1 expression, but did not alter constitutive ICAM-1 expression. Importantly, NF-κB1 knock-down also significantly reduced leukocyte binding to TNF-α-stimulated human retinal endothelial cell monolayers, but did not impact baseline binding.

Rationale
Specificity is an important consideration for success in planning a treatment approach that involves manipulating ICAM-1 expression. One candidate molecule with a primary function in regulating ICAM-1 expression is ICAM-1-related (ICR), which is a long non-coding (lnc)RNA transcribed from the anti-sense DNA strand overlapping the ICAM1-ICAM4-ICAM5 gene cluster on chromosome 19p13.2. This lncRNA was described recently in a publication by Guo et al. [9], who studied a cell line generated from portal vein thrombus of an individual with hepatocellular carcinoma [10]; the investigators showed ICR bound to and stabilized the ICAM-1 transcript, leading to increased ICAM-1 protein expression. Prior to considering ICR blockade as a treatment of retinal vasculopathy, it is essential to understand how disease-relevant stimuli trigger transcription of ICR. To date, however, the ICR promoter has not been characterized. Thus, we undertook a comprehensive in silico analysis of ICR promoter to identify potential TF binding sites (TFBSs), as well as associations between TFBSs and single nucleotide polymorphisms (SNPs). We also verified that human retinal endothelial cells expressed ICR.

Functionally constrained elements in ICR gene promoter regions
Conserved sequences across orthologous promoters may identify TFBSs of functional relevance; conserved sequences signify genomic regions that have resisted evolutionary mutation over time, implying a functional constraint [11]. Sequences for the human ICR gene and an orthologous mouse gene have been manually annotated by the HAVANA (Human and Vertebrate Analysis and Annotation) project and lodged with Ensembl [12] (human: AC011511.5 and ENSG00000267607.1; mouse: AC159314.1 and ENSMUSG00000110790). The human gene consists of a single exon that begins in the ICAM4-ICAM5 intergenic region, spans the entire ICAM4 gene, and overlaps the 3′ untranslated region (UTR) of ICAM1 (Fig. 1). The mouse gene, which is located on chromosome 9, also spans Icam4 and overlaps the 3′ UTR of Icam1, but has 2 exons: the first exon begins within intron 1 of Icam5 and continues across exon 1 of Icam5, and the second exon begins in the Icam4-Icam5 intergenic region and spans Icam4 (Fig. 1). Since locations of the transcription start site (TSS) and, by extrapolation, the promoter region, differ between human and mouse genes, we conducted separate analyses to identify regions of constrained DNA sequence across multiple eutherians.
Genomic evolutionary rate profiling (GERP) was performed using the Ensembl genome browser (Ensembl release 89-May 2017) [12] to identify evolutionarily constrained elements across annotated eutherian sequences located within the region 500 base pairs (bp) upstream of the human TSS and the mouse TSS [13]. The human genome build was GRCh38.p10, and the mouse genome build was GRCm38.p5. Genome sources for other eutherians are listed in Additional file 1: Table S1. One GERP-constrained element of 115 bp (located at − 276 to − 390 bp relative to the TSS) in the human ICR promoter was common to 25 genomes; the dolphin sequence was excluded, as the match was incomplete across the region. A second GERP-constrained element of 68 bp (located at − 177 to − 244 bp relative to the TSS) in the promoter of the orthologous mouse gene located on chromosome 9 was conserved across 27 genomes; the pika and lesser hedgehog tenrec sequences were similarly excluded due to incomplete matching. The proximity of these conserved, non-coding DNA sequences to the human or mouse TSS indicate a likely role in regulating ICR gene expression. Interestingly, the GERP-constrained element in the mouse gene is conserved in the human genome, suggesting a second ICR transcript-with two exonsmay exist in the human. Two polyadenylation signals at the 3′ end of the ICR gene are also conserved across 26 and 24 eutherian genomes, including human and mouse.

Transcription factor binding sites within conserved ICR gene promoter regions
The GERP-constrained elements-plus 10 bp upstream sequence and 10 bp downstream sequence-within the defined promoter regions of the human ICR and orthologous mouse genes were interrogated for predicted TFBSs in the 'General Core Promoter Elements' and 'Vertebrates' sections of Matrix Library 10.0 (October 2016) using MatInspector [14] in Genomatix Software Suite (http://www.genom atix.de): the 'Common TFs' search tool was used; 'Core similarity' was set at 0.75; and 'Matrix similarity' was set at optimized, to minimize false positives for individual matrices. Searching the human element identified 5 matrix families (containing 15 matrices) common to all 24 eutherian sequences, plus one additional family (containing 2 matrices) in 23 of the 24 sequences. These matrices predicted TFBSs for gene regulators including: HIF1, NRF1, MYC-MAX, BHLHE40, XBP1 and STAF. Searching the mouse element identified one matrix family (containing 8 matrices) in 24 of 25 eutherian sequences, a second family (containing 5 matrices) in 23 of 25 sequences, and a third family (containing 3 matrices) in 19 of 25 sequences. These matrices predicted TFBSs for DNA-binding factors that include: RFX1, AP-1 and BACH2. Matrix families, matrices and predicted binding sites are listed in Table 1, and sequences and locations corresponding to each matrix are provided in Additional file 2: Table S2. The spectrum of TFBSs assigned to the ICR gene promoter in our analysis is consistent with transcription in response to a wide range of pathological stimuli that include hypoxia, and metabolic and inflammatory proteins.

Single nucleotide polymorphisms in proximity to ICR gene promoter regions
We sought to identify phenotype-associated SNPs with potential to influence transcription of the human ICR gene, searching both the ICR-ICAM5 intergenic region and 100 bp downstream of the ICR TSS. We also searched intron 1 of the ICAM5 gene, since GERP suggested the mouse lncRNA might be represented in the human. Single nucleotide polymorphisms within these regions (plus 25 bp upstream sequence and 25 bp downstream sequence) were extracted from the Single Nucleotide Polymorphism Database of the US National Center for Biotechnology Information [15]. The Genomatix Software Suite SNPInspector was used to search Matrix Library (search settings as described for MatInspector analysis) for promoter elements predicted to be impacted by these SNPs. Results were checked against chromatin immunoprecipitation-sequencing data in ENCODE (Encyclopedia of DNA Elements) [16] to confirm TF binding at SNP locations. This analysis identified 3 SNPs in the defined region between ICR and ICAM5 plus 100 bp downstream of the ICR TSS (rs2569693, rs281439 and rs281440), and 2 SNPs in intron 1 of ICAM5 (rs2075741 and rs11575074) ( Fig. 1; Table 2, Additional File 3: Table S3). All these SNPs have been associated with human disease and/or serum levels of the membrane-cleaved form of ICAM-1, which is commonly referred to as soluble (s)ICAM-1.
The rs2569693 SNP has been associated with susceptibility to systemic lupus erythematosus across different human populations [17], and with sICAM-1 levels [18]. Analysis identifies the location of this SNP to coincide with binding sites for numerous TFs, including MYC and SCAN domain family members, and predicts the minor allele will cause loss of sites for MYC family member, MAZR, and SCAN domain family member, ZKSCAN3, plus gain of a site for MOK2. The minor allele at rs281439 has been associated with increased risk of breast cancer and progression of the cancer [19]. Multiple TFs, including USF family members, bind at this position, and the minor allele may code loss of the USF binding site, plus gain of E2F6, GCM1 and XCPE binding sites. The rs281440 minor allele has been linked to reduced levels of sICAM-1 [20]; it is predicted to cause no gains of binding motifs, but loss of several; however, ENCODE identified no TFs that bound this position, and thus conclusions on binding activity are not possible at this time. The minor allele at rs2075741 has been associated with breast and prostate cancer [19], and elevated levels of sICAM-1 [20]. Several TFs are predicted to bind at this site; no TFBS is lost with the minor allele, but a new MTE (designated DMTE in Genomatix Software Suite) binding sequence may be created. Similarly, analysis of rs11575074 minor allele, which also has been linked with elevated sICAM-1 levels [21] reveals no losses in known TFBSs, but sites for MYBL1, PTF1 and MEIS1-HOXA9 may be gained. Our findings suggest at least 4 of 5 SNPs are likely to influence TF binding to the ICR gene promoter, and thus alter the level of ICR and ICAM-1 expression.

Expression of ICR by human retinal endothelial cells
Given that our interest in ICR relates to its potential as a therapeutic target for ICAM-1 in retinal vasculopathy, we wanted to verify the expression and induction of ICR in endothelial cells isolated from human retinae. Tumor necrosis factor-α has been associated with the spectrum of retinal vasculopathies [1], and its signaling pathways involve TFs that recognize the TFBSs identified in our ICR promoter analysis [22,23]. We generated endothelial cell isolates from four paired human retinae, using the method that we have previously described in detail [1]. Cells were cultured in MCDB-131 medium (Sigma-Aldrich, St. Louis, MO), supplemented with 10% heat-inactivated fetal bovine serum (FBS) (HyClone-GE Healthcare Life Sciences, Logan, UT) and endothelial growth factors (EGM-2 SingleQuots supplement, omitting FBS, hydrocortisone and gentamicin; Clonetics-Lonza, Walkersville, MD) at 37 °C and 5% CO 2 in air, and used at passage 1 or 2. Confluent cells were treated with fresh medium alone or containing TNF-α (10 ng/ mL, R&D Systems, Minneapolis, MN) for 4 h, and lysed with Buffer RLT (Qiagen, Hilden, Germany). Total RNA was extracted using the RNeasy mini kit (Qiagen), and reverse-transcribed using iScript Reverse Transcription Supermix for RT-qPCR (Bio-Rad, Hercules, CA). Quantitative real-time polymerase chain reaction was performed following standard methodology, using iQ SYBRGreen Supermix (Bio-Rad) and on the CFX96 Connect Real-Time PCR Detection System (Bio-Rad) [24]. Relative expression was calculated in the Gene Expression Analysis module of CFX Manager v3.1 (Bio-Rad), which uses the 2 −ΔΔCt method [25], normalizing to two stable reference genes. Primer sequences are given in Additional file 4: Table S4. As presented in Fig. 2, we observed that retinal endothelial cell isolates from all four human retinae expressed ICR and ICAM-1. Cellular expression of ICR, as well as ICAM-1 transcript, was significantly increased (p < 0.05: Student t test, 2-tailed) following exposure to TNF-α. Both level of ICR expression and degree of induction varied between individual donors.

Limitations
• Our analysis of the ICR gene promoter focused on evolutionarily conserved genomic sequences located within 500 bp upstream of the TSS. While the majority of TFBSs are expected to lie close to the TSS, it is possible that other TFBSs exist outside these regions. • This investigation was conducted in silico, and therefore it predicts candidate TFBSs, some of which may not be confirmed in biological studies. The computational analysis was comprehensive, but also limited by the capacity of present software tools and database annotations. • We verified expression and induction of ICR in human retinal endothelial cells, since our interest in this lncRNA relates to the regulation of ICAM-1 protein expression in retinal vasculopathy. Our observations may not apply to all human cell populations.